Nieweg O E, Kim E E, Wong W H, Broussard W F, Singletary S E, Hortobagyi G N, Tilbury R S
Department of General Surgery, University of Texas M. D. Anderson Cancer Center, Houston.
Cancer. 1993 Jun 15;71(12):3920-5. doi: 10.1002/1097-0142(19930615)71:12<3920::aid-cncr2820711220>3.0.co;2-n.
An increasing number of patients with breast cancer is being treated with preoperative chemotherapy. Evaluation of treatment response may be facilitated by positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG). This noninvasive technique may allow prediction of the chemotherapy outcome in an early phase of the treatment.
Prerequisites for treatment monitoring with PET are good FDG uptake in the tumor, high specificity, and a reliable quantification technique. These factors were studied in 20 patients with primary breast cancer, lymph node metastases, benign breast lesions, a combination of these abnormalities, or no abnormality.
In 10 of 11 patients with primary breast cancer, the tumor was visualized. The median tumor-to-normal-tissue-uptake ratio was 4.9. In all five patients with increased uptake in the lymph node basin, pathologic proof of metastatic cancer was found. Of the patients with benign or no disease of the breast, slightly increased uptake was seen in one patient with fibrocystic disease.
It is concluded that PET with FDG can be used for breast cancer imaging and staging.
越来越多的乳腺癌患者接受术前化疗。正电子发射断层扫描（PET）结合18F-氟-2-脱氧-D-葡萄糖（FDG）有助于评估治疗反应。这种非侵入性技术可能在治疗早期就能够预测化疗结果。
用PET进行治疗监测的前提条件是肿瘤对FDG摄取良好、特异性高以及有可靠的定量技术。对20例患有原发性乳腺癌、淋巴结转移、乳腺良性病变、这些异常情况的组合或无异常的患者进行了这些因素的研究。
11例原发性乳腺癌患者中有10例肿瘤显影。肿瘤与正常组织摄取率的中位数为4.9。在所有5例淋巴结区域摄取增加的患者中，均发现了转移性癌的病理证据。在乳腺良性或无疾病的患者中，1例纤维囊性疾病患者的摄取略有增加。
得出结论，FDG-PET可用于乳腺癌的成像和分期。
Zotero 插件